Rothko Merger Sub, Inc., a <a href="https://laohu8.com/S/GCVRZ">Sanofi</a> Subsidiary, Extends Tender Offer for Blueprint Medicines
Rothko Merger Sub, Inc., a wholly owned subsidiary of Sanofi SA, has announced the extension of its tender offer to acquire all outstanding shares of Blueprint Medicines Corporation. The offer, initially set to expire on July 16, 2025, has now been extended until July 17, 2025. Under the terms of the offer, shareholders will receive $129.00 per share in cash, plus one non-transferable contractual contingent right per share, potentially earning up to an additional $6.00 per share, contingent upon achieving specific milestones. As of the previous deadline, approximately 45.85% of Blueprint's shares had been validly tendered, with additional shares tendered by notice of guaranteed delivery. The extension aims to meet the required conditions for completing the acquisition.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001118324-en) on July 17, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。